Literature DB >> 12514108

Inhibition of tumor angiogenesis by cannabinoids.

Cristina Blázquez1, M Llanos Casanova, Anna Planas, Teresa Gómez Del Pulgar, Concepción Villanueva, María J Fernández-Aceñero, Julián Aragonés, John W Huffman, José L Jorcano, Manuel Guzmán.   

Abstract

Cannabinoids, the active components of marijuana and their derivatives, induce tumor regression in rodents (8). However, the mechanism of cannabinoid antitumoral action in vivo is as yet unknown. Here we show that local administration of a nonpsychoactive cannabinoid to mice inhibits angiogenesis of malignant gliomas as determined by immunohistochemical analyses and vascular permeability assays. In vitro and in vivo experiments show that at least two mechanisms may be involved in this cannabinoid action: the direct inhibition of vascular endothelial cell migration and survival as well as the decrease of the expression of proangiogenic factors (vascular endothelial growth factor and angiopoietin-2) and matrix metalloproteinase-2 in the tumors. Inhibition of tumor angiogenesis may allow new strategies for the design of cannabinoid-based antitumoral therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12514108     DOI: 10.1096/fj.02-0795fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  71 in total

1.  Angiogenesis: a new physiological role for N-arachidonoyl serine and GPR55?

Authors:  W-S V Ho
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.

Authors:  Luciano De Petrocellis; Alessia Ligresti; Aniello Schiano Moriello; Mariagrazia Iappelli; Roberta Verde; Colin G Stott; Luigia Cristino; Pierangelo Orlando; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

3.  Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis.

Authors:  Anju Preet; Zahida Qamri; Mohd W Nasser; Anil Prasad; Konstantin Shilo; Xianghong Zou; Jerome E Groopman; Ramesh K Ganju
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-19

Review 4.  CB2 receptor-mediated migration of immune cells: it can go either way.

Authors:  A M Miller; N Stella
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

Review 5.  Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Authors:  P Pacher; G Haskó
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

6.  Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis.

Authors:  Mohanraj Rajesh; Hao Pan; Partha Mukhopadhyay; Sándor Bátkai; Douglas Osei-Hyiaman; György Haskó; Lucas Liaudet; Bin Gao; Pál Pacher
Journal:  J Leukoc Biol       Date:  2007-07-25       Impact factor: 4.962

7.  CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion.

Authors:  Mohanraj Rajesh; Partha Mukhopadhyay; Sándor Bátkai; György Haskó; Lucas Liaudet; John W Huffman; Anna Csiszar; Zoltan Ungvari; Ken Mackie; Subroto Chatterjee; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-07-27       Impact factor: 4.733

8.  Endocannabinoid system and the expression of endogenous ceramides in human hepatocellular carcinoma.

Authors:  Jiayong Yang; Yifeng Tian; Ruihe Zheng; Lei Li; Funan Qiu
Journal:  Oncol Lett       Date:  2019-05-27       Impact factor: 2.967

9.  CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration.

Authors:  M Rajesh; P Mukhopadhyay; G Haskó; J W Huffman; K Mackie; P Pacher
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

10.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.